Canada markets close in 3 hours 20 minutes

Avivagen Inc. (VIV.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.42500.0000 (0.00%)
As of 10:32AM EDT. Market open.
Full screen
Previous Close0.4250
Open0.4250
Bid0.4250 x 0
Ask0.4400 x 0
Day's Range0.4250 - 0.4250
52 Week Range0.4000 - 0.7700
Volume900
Avg. Volume34,741
Market Cap17.751M
Beta (5Y Monthly)1.71
PE Ratio (TTM)N/A
EPS (TTM)-0.1200
Earnings DateMar. 04, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.90
  • Business Wire

    Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants

    Avivagen Inc. (TSXV:VIV) ("Avivagen" or the "Corporation"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely support immune function, promote general health and performance, announces that it has received approval by the TSX Venture Exchange to extend the expiry date of certain of its outstanding warrants.

  • Business Wire

    Avivagen Inc. Announces Proposed Extension of Warrants

    Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) ("Avivagen" or the "Corporation"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, announces that it will be requesting approval from the TSX Venture Exchange for the extension of the expiration date of warrants exercisable to purchase 2,774,992 common shares at $0.90 per share, which were originally issued on June 1, 2016. These warrants currently have an expiration date of September 30, 2020. Subject to TSX Venture Exchange approval, the new date of expiry for such warrants will be March 31, 2021. All other terms of such warrants will remain unchanged.

  • Business Wire

    Avivagen Inc. Announces Record Revenue for the Third Quarter Ending July 31, 2020

    Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) ("Avivagen" or the "Corporation"), a world leader in natural alternatives to antibiotics with its OxC-beta™ technology, has announced its unaudited financial results for the third quarter of 2020.